Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
The Journal of infection - 81(2020), 6 vom: 01. Dez., Seite 979-997 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sagnelli, Caterina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 07.01.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2020.05.043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31054484X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31054484X | ||
| 003 | DE-627 | ||
| 005 | 20231225140329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2020.05.043 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM31054484X | ||
| 035 | |a (NLM)32474034 | ||
| 035 | |a (PII)S0163-4453(20)30322-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sagnelli, Caterina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.01.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Methylprednisolone |2 NLM | |
| 650 | 7 | |a X4W7ZR7023 |2 NLM | |
| 700 | 1 | |a Gentile, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Tirri, Rosella |e verfasserin |4 aut | |
| 700 | 1 | |a Macera, Margherita |e verfasserin |4 aut | |
| 700 | 1 | |a Cappabianca, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccia, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Coppola, Nicola |e verfasserin |4 aut | |
| 700 | 0 | |a Vanvitelli COVID-19 group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 81(2020), 6 vom: 01. Dez., Seite 979-997 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2020 |g number:6 |g day:01 |g month:12 |g pages:979-997 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2020.05.043 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2020 |e 6 |b 01 |c 12 |h 979-997 | ||